Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction

NCT04788511 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT04788511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04788511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
March 16, 2021
Completion date
April 18, 2023
Enrollment
529 (actual)
Sites
146

Conditions

As the registry lists them; a condition with its own page is linked.

obesity